Lifecore Biomedical (LFCR) Stock
Medical materials company focused on hyaluronic acid. Here's the price, business snapshot, and what's worth knowing about Lifecore Biomedical in October 2026.
Lifecore Biomedical (LFCR) is a small-cap medical materials company focused on hyaluronic acid (HA) — a naturally occurring polymer used in ophthalmic, orthopaedic, aesthetic and regenerative-medicine applications. The company operates both product lines and contract development and manufacturing (CDMO) services, supplying customised HA solutions and sterile-fill manufacturing to medical-device and pharmaceutical customers. Investors should note Lifecore’s dual exposure to product demand and outsourced manufacturing trends: stable OEM partnerships can provide recurring revenue, while product innovation and regulatory approvals can unlock new markets. At a market cap of around $253m, the stock can be more volatile than larger peers and is sensitive to customer concentration, regulatory outcomes and capital-spend cycles. Evaluate Lifecore by reviewing revenue growth, gross margins, backlog, and cash flow, and consider industry risks. This is general educational information, not personalised investment advice; values can fall as well as rise.
Lifecore Biomedical (LFCR) Stock Forecast
Analyst price target, next 12 months
$7.66
+17.1% vs today's $6.54
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Lifecore Biomedical have a consensus 12-month target of $7.66, above the current price of $6.54.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 May 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding LifeCore Biomedical's stock, with a target price indicating room for growth.
Financial Health
Lifecore Biomedical is generating moderate revenue and cash flow, but faces challenges with profitability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Dual Revenue Streams
Products and CDMO services give two potential growth levers, though performance can vary with customer demand and contract timing.
Manufacturing Edge
Specialist sterile-fill and HA expertise can attract OEM partners, but operations are capital and regulation intensive.
Market Exposure
Serves ophthalmic, orthopaedic and aesthetic markets with global opportunity, yet subject to regulatory and competitive headwinds.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
